Celldex Therapeutics (CLDX) Gains on CDX-0159 Update, Which Has Drug 'In the Driver's Seat'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- AI stocks lift Wall St as oil falls, Treasury yields decline
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- AMD stock jumps as chip rally builds ahead of summit
Celldex Therapeutics Presents Positive Data from CDX-0159 Phase 1b Study in Chronic Inducible Urticaria at EAACI 2021
July 9, 2021 6:01 PM EDT- 95% complete response rate after single dose of CDX-0159 -- Rapid, profound and durable responses offer patients opportunity for quick, lasting, meaningful relief -- Median duration of response 77+ days in Cold Urticaria and 57+ days in Symptomatic Dermographism -- Serum tryptase and skin mast cell depletion mirror clinical activity -- Favorable safety profile -- Company to host webcast conference call on Monday, July 12 at 8:15 a.m. ET -
HAMPTON, N.J., July 09, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced updated data... More
